HTGC

Hercules is a business development company (BDC) lending to venture-backed tech and life-sciences firms at 7–14% rates, taxed as a RIC that must distribute nearly all income — so it lives or dies by credit quality and net asset value, not GAAP 'revenue' (which is why no revenue line is reported). The franchise looks healthy: FY2025 net income of $340M (+29.2%) and diluted EPS of $1.85 (+14.9%) drove a 15.3% ROE, the auditor issued a clean opinion with effective internal controls, and leverage is conservative at 1.07x liabilities/equity — well below the 2:1 regulatory ceiling, leaving capacity to grow the book. At $15.88 that's 8.6x EPS, and the $326M dividend (~$1.77/share, roughly 11% yield) is covered by $1.85 of EPS.

The catch is valuation framed correctly. For a BDC the right yardstick is price-to-NAV, not P/E: equity of $2.22B over 184M shares is ~$12.07 book value, so the stock trades at ~1.3x NAV — a premium the market awards Hercules for its track record, not a discount. That premium is the ceiling on upside. The earnings stream is also lumpier than the headline implies (net income ran $174M→$102M→$337M→$263M→$340M), reflecting mark-to-market swings on warrants and equity kickers rather than steady spread income. The 10-K flags $55.9M of non-cash PIK income that must still be distributed to keep RIC status, sometimes funded by selling assets — a quality flag worth watching.